AMPK、NF-κB、COX-2及PGE2在非小细胞肺癌中的表达

Expressions of AMPK, NF-κB, COX-2 and PGE2 in non-small cell lung cancer

摘要:

摘要：目的  探讨腺苷酸活化蛋白激酶（AMPK）、核因子κB（NF-κB）、环氧合酶2（COX-2）及前列腺素E2（PGE2）在非小细胞肺癌（NSCLC）中的表达及其关系。方法  采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连接法检测NSCLC和正常肺组织标本中可以直接反映AMPK激活状态的乙酰辅酶A羧化酶磷酸化后的产物（P-ACC）、NF-κB、COX-2的表达，实时荧光定量聚合酶链反应（qRT-PCR）和Western blot检测NSCLC标本及血液、正常肺组织标本及血液中AMPK、COX-2及PGE2受体的表达。结果  免疫组织化学法检测发现，P-ACC在NSCLC中低表达，NF-κB和COX-2在NSCLC中高表达，其阳性率分别为33.9%、75.8%和66.1%，且与正常肺组织中的表达差异有统计学意义；qRT-PCR和Western blot检测发现，在NSCLC标本及血液中，AMPK mRNA表达降低，COX-2和PGE2受体mRNA表达升高。结论  在NSCLC中，AMPK低表达，NF-κB、COX-2及PGE2高表达，其相互作用可能在NSCLC的增殖、凋亡耐受、侵袭及转移过程中占据重要位置，其表达情况为临床治疗NSCLC提供新的思路。

Abstract:

Abstract: Objective To discuss the expressions and relations of AMP-activated protein kinase (AMPK), nuclear factor-κB (NF-κB), cyclooxygenase 2 (COX-2) and prostaglandin E2 (PGE2) in non-small cell lung cancer (NSCLC). Methods The expressions of phosphorylation product of acetyl coenzyme A carboxylase (P-ACC, which could directly reflect active AMPK), NF-κB and COX-2 in NSCLC and normal lung tissue specimens were detected by immunohistochemical SP method. The expressions of AMPK, COX-2 and EP2 in NSCLC, normal lung tissues and blood specimens were detected by qRT-PCR and Western blot. The SPSS 22.0 software package was used for statistical analysis. Results The positive expression rate of P-ACC in the NSCLC specimens was 33.9% which was significantly lower than that in the normal lung tissue; while the positive expression rates of NF-ΚB and COX-2 in the NSCLC specimens were 75.8% and 66.1% respectively, which were significantly higher than those in the normal lung tissue. The expression of AMPK mRNA was reduced, while the expressions of COX-2 mRNA and PGE2 mRNA increased in the NSCLC specimens and blood, there were significant differences. Conclusions Low-expression of AMPK and high-expressions of NF-κB, COX-2 and EP2 in NSCLC may play important roles in NSCLC proliferation, apoptosis tolerance, invasion and metastasis. These different expressions provide a new idea for clinical treatment of NSCLC.